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ABSTRACT
According to the threshold concept, FSH concentrations need to
surpass a distinct level to stimulate ovarian follicle growth. The win-
dow concept stresses the significance of a limited duration of elevated
FSH levels above the threshold for single dominant follicle selection.
The aim of this study was to investigate effects on follicle growth of
increased FSH levels, differing in duration and magnitude of eleva-
tion, during the follicular phase. Twenty-three normo-ovulatory (cycle
length, 26–31 days), young (age, 20–31 yr) women volunteered for
this study. In all subjects a series of daily transvaginal sonography
scans of the ovaries and blood sampling [for FSH and estradiol (E2)
determinations] were performed during two consecutive cycles. The
first study cycle (control cycle) started 10 days after urinary assess-
ment of the LH surge in the preceding cycle (DayLH) and was con-
cluded on the day of ovulation assessed by transvaginal sonography
scans. The second series of daily monitoring (intervention cycle)
started 10 days after DayLH in the control cycle. After randomization,
subjects received either 375 IU urinary FSH, sc, as a single injection
on DayLH114 (group A; n 5 11) or 75 IU daily from DayLH119 until
DayLH123 (group B; n 5 12).
In group A, FSH levels increased on the day after injection to a
median concentration of 10.1 IU/L, which was 1.9 times higher (P ,
0.01) than levels on matching days during the control cycle. Concen-
trations returned to basal levels 3 days after injection. In group B, a
moderate elevation of FSH concentrations (15% increase; P , 0.05)
was observed compared to levels during the control cycle. In group A,
E2 concentrations increased (P 5 0.03) 1 day after FSH injection and
returned to baseline levels within 2 days. In group B, E2 levels started
to increase after the first injection of FSH and remained significantly
higher (P , 0.01) during the following 5 days compared to those on
matching days in the control cycle. Compared to matching days in the
control cycle an increased number of follicles 8–10 mm in size was
found in group A (P , 0.01) during the period from DayLH114 until
DayLH119, without an increase in follicles 10 mm or larger thereafter.
In contrast, in group B, the numbers of both 8- to 10-mm and 10-mm
or larger follicles were higher during the period from DayLH119 until
DayLH124 in group B (P 5 0.02 and P , 0.01, respectively).
Results from the present study suggest that a brief, but distinct,
elevation of FSH levels above the threshold in the early follicular
phase does not affect dominant follicle development, although the
number of small antral follicles did increase. In contrast, a moderate,
but continued, elevation of FSH levels during the mid to late follicular
phase (effectively preventing decremental FSH concentrations) does
interfere with single dominant follicle selection and induces ongoing
growth of multiple follicles. These findings substantiate the FSH
window concept and support the idea of enhanced sensitivity of more
mature follicles for stimulation by FSH. These results may provide
the basis for further investigation regarding ovulation induction
treatment regimens with reduced complication rates due to over-
stimulation. (J Clin Endocrinol Metab 83: 1292–1298, 1998)
AS FSH LEVELS increase during the luteo-follicular tran-sition of the menstrual cycle, a cohort of small antral
follicles is prevented from undergoing atresia and is stimu-
lated for further development (1–4). The FSH threshold con-
cept has been proposed, emphasizing the need for serum
FSH to surpass a distinct concentration to induce ovarian
activity (5–7). Based on observations during gonadotropin
induction of ovulation, Brown suggested that an elevation of
FSH concentrations only 10–30% above the threshold level is
sufficient to stimulate normal follicle development, whereas
a further increase causes excessive stimulation (5). Indeed,
multiple follicle development and ovulation have been at-
tributed to higher elevations of FSH above the threshold level
(8, 9).
Circulating FSH levels decrease in the late follicular phase
of the normal menstrual cycle, supposedly due to increased
secretion of ovarian factors such as estradiol (E2) and inhibin
B, which exert negative feedback at the hypothalamic-pitu-
itary level (10, 11). The strict relationship between decreasing
FSH concentrations and dominant follicle development in
the normal menstrual cycle has been established recently by
our group (12), emphasizing the importance of decreasing
FSH levels in securing single dominant follicle selection.
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Apparently, the maturing dominant follicle requires less FSH
to continue its growth (13, 14). This may be due to intrao-
varian changes in growth factors, which up-regulate the FSH
sensitivity of follicles in more advanced developmental
stages (15). As a consequence, other recruited follicles lack
sufficient stimulation by FSH and enter atresia. In this re-
gard, the “FSH-gate” (2) or “FSH-window” (16) concept has
been proposed, which adds the element of time to the FSH
threshold theory and emphasizes the significance of a tran-
sient increase in FSH above the threshold level for single
dominant follicle development. Indeed, as has been demon-
strated in primates, interference with the decrease in FSH
levels in the midfollicular phase overrides selection of a
single dominant follicle (17). Moreover, administration of
gonadotropins for induction of ovulation in the human, ap-
plying a decremental dose regimen, has proven successful in
reducing the incidence of multiple follicle development (18,
19).
Further insight into the significance of the pattern of FSH
stimulation for recruitment and dominant follicle selection
may provide a basis for understanding mechanisms under-
lying follicle maturation arrest in polycystic ovary syndrome
patients, for improved treatment regimens for gonadotropin
induction of ovulation, and for effective suppression of re-
sidual ovarian activity during the pill-free interval of steroid
contraception (4). The principal aim of the present study was
to examine to what extent elevation of FSH levels, differing
in duration and magnitude, would affect follicle develop-
ment. For this purpose, FSH was administered at different
times and dosages to women exhibiting normal ovarian func-
tion to elicit either an increase in FSH concentrations far
above the threshold level in the early follicular phase or a
moderate, but prolonged, FSH increase in the mid to late
follicular phase.
Subjects and Methods
Subjects and study design
This study was approved by the ethics review committee of the
Academic Hospital and Erasmus University Medical School (Rotterdam,
The Netherlands). A total of 26 study subjects was selected from re-
spondents to an advertisement in a local newspaper. Inclusion criteria
were age between 20–33 yr, regular menstrual cycles for at least 3
months before the study (cycle lengths between 26–31 days), and no oral
contraceptive use or other medical or hormonal treatment for at least 3
months before study initiation. In addition, subjects were required to be
of normal weight (body mass index, 19–25 kg/m2) and to have never
received treatment for infertility. During the study, subjects were re-
quired to use sufficient contraceptive measures, such as intrauterine
devices, tubal ligation, or condoms. Informed written consent was ob-
tained from each participant, and all 26 subjects were paid for their
participation. Fourteen subjects had been pregnant previously.
Subjects were studied during three subsequent cycles. From 10 days
after the onset of menses, subjects assessed the LH surge using a urinary
LH test (Clear-Plan One Step, Unipath, Bedford, UK) according to the
manufacturer’s instructions. Six or 7 days after a positive urinary LH
test, a blood sample was taken for assessment of midluteal progesterone
(P). From 12 days after the LH surge, a series of daily transvaginal
ultrasound scans (TVS) and blood sampling was performed (control
cycle). Daily investigations for each subject took place between 1200–
1700 h and were concluded on the day of sonographically assessed
ovulation [decrease in size of .50% of the largest ($18 mm) follicle].
Normal ovulation was confirmed by assessment of elevated P levels
(.18 nmol/L) 6 or 7 days later (12).
A second series of daily TVS and blood sampling started 10 days after
the onset of the LH surge (intervention cycle). The day of the LH surge
(DayLH) was assessed by measurement of serum LH in the control cycle
and was defined as the day on which the LH level was highest or as the
first LH level that was at least 3 times higher than the level on the
previous day. On the 12th day after the LH surge, subjects were ran-
domly assigned to one of two intervention schedules (designated group
A and group B, respectively). Randomization was performed by number
in blocks of three pairs by drawing of a sealed envelope indicating the
assigned group. The administration of urinary FSH (Metrodin HP of the
same batch, provided by Serono Benelux, BV, The Hague, The Neth-
erlands) was performed by a third party, with the assigned protocol
unknown to the observer (I.S.). Group A received 375 IU (five ampules)
FSH as a single sc injection on the 14th day after the LH surge, effectively
increasing FSH concentrations far above the presumed threshold level
for a brief period of time in the early follicular phase. Group B received
75 IU (one ampule) of FSH sc daily during 5 consecutive days from 19–23
days after the LH surge, thereby preventing decremental serum FSH
concentrations in the mid to late follicular phase, thus widening the FSH
window. FSH was administered by qualified nurses shortly after the
daily blood withdrawal, with the next blood withdrawal 24 h later. Daily
TVS and blood sampling continued until the day of ovulation in the
intervention cycle. Again, normal ovulation was confirmed by assess-
ment of elevated P levels 7 days later.
Sonographic examinations were performed by the same observer
(I.S.) using a 6.5-megahertz transvaginal transducer (EUB-415, Hitachi
Medical Corp., Tokyo, Japan) as described previously (12, 20). In brief,
follicle diameter was calculated as the mean diameter measured in two
dimensions if both diameters were 9.0 mm and in three dimensions if
at least one diameter was more than 9.0 mm.
Hormone estimations
Blood samples were centrifuged within 2 h after withdrawal and
stored at 220 C until assayed. FSH and LH levels were measured by
immunoradiometric assay (Medgenix, Fleurus, Belgium) as described
previously (21). P levels were assessed by RIA as described previously
(22), and E2 levels were estimated using RIA kits provided by Diagnostic
Products Corp. (Los Angeles, CA). Intra- and interassay coefficients of
variation were less than 3% and less than 8% for FSH, less than 5% and
less than 15% for LH, less than 16% and less than 17% for P, and less than
15% and less than 18% for E2, respectively. All samples from one subject
were run in the same assay.
Data analysis
Data are presented as the mean 6 sd if distributed normally or as the
median and range if distributed otherwise. The time scale used is based
on the day of the preceding LH surge (DayLH). The day of selection of
the dominant follicle is defined as the day on which a given follicle was
10 mm or larger together with an enlargement of this follicle during
subsequent days until ovulation, as described previously (12, 20). The
day of the E2 rise is defined as the day during the follicular phase on
which E2 concentrations were significantly higher compared to those on
the preceding days and continued to increase thereafter until ovulation.
This was estimated using piecewise linear regression relating log(E2) to
cycle day, as described previously (12).
The effects of both interventions was estimated by comparison of the
area under the curve (AUC) of FSH and E2 for a given number of days.
AUCs were calculated for each subject individually during two periods
of the follicular phase of the menstrual cycle using the trapezoidal rule
method. Period 1 was arbitrarily defined to comprise DayLH114 until
DayLH119, and period 2 comprised DayLH119 until DayLH124 based on
FSH administration regimens. As a reflection of follicle growth, the total
number of follicles observed (divided into size classes of 8–10 mm and
$10 mm) was calculated for the same periods.
Statistical analysis was performed using Wilcoxon’s test for matched
pairs for comparison between the control cycle and the intervention
cycle for each group. Comparisons of outcome measures between both
randomized groups were performed using the Mann-Whitney U test.
Power analysis (50.20) showed that the sizes of both intervention groups
allowed for detection (50.05) of differences in outcome parameters of 1.1
sd. Spearman’s correlation coefficients are indicated. P values are two-
sided, with 0.05 taken as the limit for statistical significance.
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Results
FSH and E2 levels during control and intervention cycles
Two of the 26 subjects were excluded from further analysis
due to an irregular control cycle and/or anovulation during
the control cycle. A third subject was excluded due to mul-
tiple persisting cysts at the onset of the intervention cycle in
combination with an insufficient luteal phase in the preced-
ing control cycle. All remaining 23 subjects were ovulatory
in both the control and the intervention cycle, as assessed by
TVS and elevated serum P levels (38 6 10 nmol/L) 7 days
after sonographically assessed ovulation. After the control
cycle, 11 subjects were randomized for the intervention cycle
into group A, and 12 were randomized into group B. With
regard to the distribution of age and body mass index, no
significant differences were found between the two groups
(data not shown).
Due to the design of the study, serum FSH levels are
presented with the LH surge from the preceding cycle as the
point of reference. This is for reasons of comparison between
the control and intervention cycles and does not represent
accurately individual patterns of serum FSH concentrations.
In the intervention cycle in group A (Fig. 1a, top right panel),
in all subjects FSH levels reached a maximum level 1 day
after sc administration of 375 IU FSH on DayLH114, with a
median concentration of 10.1 IU/L (range, 7.9–13.9). FSH
levels remained significantly elevated (P , 0.01) for 2 days
and returned to levels similar to those in the control cycle on
DayLH117 [median levels, 5.0 (range, 2.4–7.3) and 5.5 (range,
4.1–9.6) IU/L in control and intervention cycles, respective-
ly]. In all subjects a second, endogenous increase in FSH
reached its maximum level on DayLH121 (range, DayLH118 to
DayLH130). The median concentration of these maximum
FSH levels in the intervention cycle was not different from
the corresponding levels in the control cycle [5.7 (range,
3.7–7.4) and 5.7 IU/L (range, 4.2–6.6), respectively]. In group
B, daily sc administration of 75 IU FSH on DayLH119 until
DayLH123 resulted in FSH levels 15% (range, 6–37%) higher
compared than those on matching days during the control
cycle (P , 0.05; Fig. 1a, bottom right panel).
In response to administration of 375 IU FSH on DayLH114
in group A, E2 levels were significantly elevated on DayLH115
and DayLH116 compared to levels before injection (P , 0.01)
and to levels on matching days in group B (P , 0.01). After
this increase, E2 levels returned to basal levels on DayLH117
(Fig. 1b, top right panel). One day after administration of the
first injection of 75 IU FSH in group B, E2 levels increased
significantly compared to those during both the control cycle
and the intervention cycle of group A on matching days (P ,
0.01). Although the day of the E2 rise occurred earlier in the
intervention cycle of group B than in the control cycle (P 5
0.03), the median preovulatory E2 levels were not statistically
different [1040 (range, 380-1800) and 900 (390–1300) pmol/L,
respectively]. Furthermore, the median preovulatory E2 lev-
els in group B were not statistically different from those in
group A (810 pmol/L; range, 550-1100).
Follicle development during control and intervention cycles
Figure 2 shows the mean number of 8-mm follicles in both
ovaries during the follicular phases of the control cycle and
the intervention cycle of groups A and B. Follicles less than
8 mm have been omitted from the graphs because analysis
of follicle numbers in smaller size classes did not display
significant differences (data not shown).
After administration of 375 IU FSH on DayLH114 in group
A, an increase in the number of 8- to 10-mm follicles was
observed (P , 0.05), however without ongoing growth to
sizes beyond 10 mm on subsequent days. In group B, daily
administration of 75 IU FSH from DayLH119 until DayLH123
did not result in a statistically significant increase (P 5 0.8)
in the mean number of 8- to 10-mm follicles compared to that
in the control cycle. However, during the following days an
increasing number of follicles 10 mm or larger was observed
(P , 0.05), suggesting ongoing growth of these follicles.
AUC for FSH and E2 and the total number of follicles
during control and intervention cycles
The median AUC for FSH of period 1 (from DayLH114 until
DayLH119) in the intervention cycle in group A was signif-
icantly higher compared to that during the same period in the
control cycle [median AUC period 1, 37 (range, 32–49) vs. 27
(range, 17–34) IU day/L; P 5 0.004]. The AUC for FSH during
period 2 in the intervention cycle in group B (DayLH119 until
DayLH124) was significantly higher than that in the control
cycle [34 (range, 23–46) and 28 (range, 21–39) IU/day/L,
respectively; P 5 0.002; Fig. 3, top panel]. During the inter-
vention cycle, the median AUCs of period 1 in group A and
period 2 in group B were not significantly different (P 5 0.15)
from each other.
Despite the short, but significant, increase in E2 levels on
DayLH115 and DayLH116 in response to administration of FSH
in group A, the AUC for E2 of period 1 was not significantly
different from that of the control cycle [1440 (range, 940-1853)
vs. 1162 (range, 678-3604) pmol/day/L; P 5 0.33]. In contrast,
in group B, a significantly higher AUC for E2 was observed
during period 2 of the intervention cycle compared to that
during the control cycle [2144 (range, 1799–2799) and 1361
(range, 992-2463) pmol/day/L, respectively; P , 0.01]. Com-
paring both groups during period 2 in the intervention cycle,
the AUC for E2 in group B was greater than that in group A
[median AUC, 2144 (range, 1799–2799) vs. 1223 (range, 818-
2423) pmol/day/L, respectively; P , 0.01].
After administration of 375 IU FSH on DayLH114 in group
A, a significant increase in small (8–10 mm) follicles was
observed during period 1 compared to that during a similar
period in the control cycle [6 (range, 1–22) vs. 1 (range, 0–8)
follicles; P , 0.01; Fig. 3, bottom panel]. After daily adminis-
tration of 75 IU FSH in group B, a statistically significant
increased number of small (8–10 mm) follicles as well as an
increased number of follicles 10 mm or larger was observed
compared to those during the control cycle during period 2
(Fig. 3, bottom panel, right graph; P 5 0.02 and P , 0.01,
respectively). The latter was reflected by an increase in the
number of follicles sized 12–15 mm [mean, 0.9 (range, 0–3)
and 2.9 (range, 0–9) in control and intervention cycle, re-
spectively; P 5 0.02] and follicles larger than 15 mm [mean,
0.7 (range, 0–3) and 1.4 (range, 0–4), respectively; P , 0.02].
Furthermore, during period 2, a higher number of follicles 10
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mm or larger was observed in group B compared to group
A (mean, 7.4 and 4.3, respectively; P 5 0.05).
Discussion
At the onset of the menstrual cycle, a cohort of small (2–5
mm) antral follicles is present in the ovaries (3). This cohort
will continue to grow in response to stimulation by FSH (23),
a process referred to as follicle recruitment (1). The FSH
threshold concept has been proposed in the late 1970s by
Brown (5) on the basis of serum estrogen levels secreted by
developing follicles and more recently has been substanti-
ated by others by sonographical assessment of follicle growth
(9, 24). According to the FSH threshold concept, increasing
FSH concentrations should surpass a distinct level to initiate
the final gonadotropin-dependent phase of follicle growth.
Some researchers suggest selection of a follicle destined to
gain dominance to occur during this period (23, 25, 26),
although direct evidence to support this idea is lacking.
FIG. 1. Daily follicular phase FSH (A)
and E2 (B) serum concentrations during
control (left panel) and intervention cy-
cles in 23 regularly cycling women.
Data are shown as the median and
range, and the time scale is expressed
as days from the preceding LH surge
(DayLH). Intervention cycle group A
(upper right panel) represents admin-
istration of a single sc injection of 375
IU FSH on DayLH114, whereas group B
(lower right panel) represents five sc in-
jections of 75 IU FSH daily from
DayLH119 until DayLH123. The inter-
vention cycle has been divided arbi-
trarily into two periods: period 1
(DayLH114 until DayLH119) and period 2
(DayLH119 until DayLH124). Asterisks
indicate statistically significant higher
levels compared to matching days in the
control cycle (P , 0.05).
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Moreover, it has been hypothesized that follicles exhibit dif-
ferent degrees of FSH sensitivity at the time of recruitment.
The follicle with the highest sensitivity will benefit most from
increasing FSH levels and will subsequently gain dominance
(27).
As opposed to ovarian hyperstimulation for in vitro fer-
tilization, the aim of induction of ovulation is to stimulate
single dominant follicle development and ovulation. FSH
levels are elevated above the threshold by daily administra-
tion of gonadotropins. Conventional treatment protocols are
often complicated by the occurrence of multiple follicle de-
velopment, which may result in ovarian hyperstimulation
syndrome or multiple pregnancies. It has been proposed that
multiple follicle development is induced by elevating FSH
concentrations far above the threshold (6). By starting with
a lower dose of gonadotropins and stepwise small incre-
ments, chances of inducing monofollicular growth should
increase with a concomitant reduction of complications. This
regimen is referred to as the low dose, step-up protocol (28,
29). However, these stimulation protocols are characterized
by FSH concentrations remaining above the threshold
throughout the follicular phase, which may interfere with
single dominant follicle selection. Indeed, it has been dem-
onstrated that the extent of accumulation of FSH in the late
follicular phase determines the magnitude of the ovarian
response (30).
FSH concentrations reach a maximum in the early follic-
ular phase of the normal menstrual cycle and decrease there-
after. The significance of this timely decrease in FSH to en-
sure monofollicular development has been demonstrated
previously in primates (13, 31) as well as in the human (12).
These findings indicate that the dominant follicle requires
less FSH to continue its development, probably due to in-
duction of locally acting factors, such as various growth
factors or the induction of LH receptors that enhance FSH
sensitivity (15). It is less likely that factors interfering with
FSH receptor binding and activation are involved in this
regulation (32). Although the dominant follicle continues its
maturation, decreasing FSH concentrations fall below the
threshold level of less mature follicles of the recruited cohort.
Consequently, these follicles cannot sustain their growth and
become atretic. On the basis of these findings, the FSH win-
dow concept has been proposed, stressing the significance of
the (limited) duration of FSH elevation above the threshold
level rather than the height of the elevation of FSH for single
dominant follicle selection (4, 16). In line with the FSH win-
dow concept, application of a decremental dose regimen for
safe and effective gonadotropin induction of ovulation, mim-
icking the dynamics of normal follicular phase FSH levels,
has proven successful (18, 19).
The present study, administering exogenous FSH to reg-
ularly cycling women, demonstrates that a distinct, but short,
increase in FSH levels in the early follicular phase around the
onset of menses induces an increased growth of small fol-
licles during subsequent days. However, dominant follicle
growth (beyond a size of 10 mm) is not affected. In contrast,
a slight, but extended, elevation of FSH levels during the mid
to late follicular phase, effectively preventing the physiolog-
ical decrease in FSH concentrations, did result in the devel-
opment of multiple dominant follicles. The present results
correspond partly with conclusions drawn from a recent
study (33). A single injection of 450 IU FSH to ovulatory
women (suffering from unexplained infertility) on cycle day
2 and additional FSH administration (one to three ampules
FIG. 2. Number of follicles (8 mm) dur-
ing the follicular phase of control (left
panel) and intervention cycles in 23 reg-
ularly cycling women. Areas represent
the mean number of follicles in both ova-
ries on a given day in all subjects, with
shaded areas representing different size
classes (see legend). The time scale is ex-
pressed as days from the preceding LH
surge (DayLH). Intervention cycle group
A (upper right panel) represents admin-
istration of a single sc injection of 375 IU
FSH on DayLH114, whereas group B (low-
er right panel) represents five sc injec-
tions of 75 IU FSH daily from DayLH119
until DayLH123. The intervention cycle
has been divided arbitrarily into two pe-
riods:period1 (DayLH114 untilDayLH119)
and period 2 (DayLH119 until DayLH124).
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daily) during subsequent days resulted in an increased num-
ber of preovulatory follicles dependent on the dose of FSH
administered. The researchers concluded that supraphysi-
ological FSH levels in the early follicular phase are a pre-
requisite for the induction of multiple follicle development,
although the number of preovulatory follicles was deter-
mined by the height of FSH levels during later stages of the
follicular phase. Observations from the present study show
that multiple dominant follicle development can be induced
by a minor interference with late follicular phase FSH levels
only. This is further supported by previous observations
from our group suggesting that the magnitude of the late
follicular phase decrease in endogenous serum FSH levels
determines dominant follicle development and related E2
production (12). In the present study, analysis of the number
and size of follicles just before ovulation is of limited sig-
nificance because exogenous FSH was administered for a
fixed number of days relative to the preceding LH surge,
resulting in a variable number of days without exogenous
FSH before ovulation.
The more than 2-fold increase in FSH concentrations (after
administration of 375 IU FSH) in the early follicular phase can
be regarded as well above the threshold level. Moreover,
observed maximum levels may even be an underestimation
of actual maximum concentrations because serum FSH was
assessed 24 h after injection. It has been reported previously
that a single injection of FSH in normal men resulted in
maximum FSH levels 6–8 h thereafter, with a 30–50% de-
crease after 24 h (34). Although the same applies for FSH
administered to group B, FSH concentrations in this group
should be considered less above the threshold level than
those in group A. Distinct differences in dominant follicle
growth comparing both groups stress the significance of
timing and duration of the FSH elevation as opposed to the
FSH concentration per se. It may be proposed that recruited
follicles increase their sensitivity to FSH during the course of
their development (13, 14), supposedly due to the induction
of a variety of autocrine factors (15, 35–37).
Induction of the aromatase enzyme during follicle recruit-
ment has been proposed to determine selection of the dom-
inant follicle (2, 25, 38). Indeed, E2 concentrations in serum
increase abruptly from the day a dominant follicle can be
visualized by TVS (12, 20). Moreover, high E2 concentrations
in the antral fluid of follicles beyond 10 mm in size indicate
that aromatase activity is particularly expressed in dominant
follicles (39). The present study shows that a short surge of
supraphysiological concentrations of FSH is capable of stim-
ulating aromatase activity in small antral follicles. However,
E2 production is not sustained even though FSH levels after
the surge are similar compared to normal follicular phase
concentrations. It may, therefore, be disputed whether in-
duction of aromatase activity in small antral follicles is a
determining factor for dominant follicle selection rather than
a feature of the dominant follicle after selection.
Results from the present study are supportive of the FSH
window concept, which stresses the importance of a limited
duration of elevated FSH levels above the threshold, as op-
posed to the magnitude of FSH increase for follicle selection
and dominance. The significance of a timely decrease in FSH
levels to ensure single dominant follicle development may be
relevant for gonadotropin induction of ovulation protocols
(4). As shown recently, ovulation induction applying a dec-
remental dose regimen (step down protocol) may result more
frequently in monoovulatory cycles and reduced chances for
complications (19). Findings from the present study may also
provide a basis for further investigation regarding follicle
maturation arrest in polycystic ovary syndrome patients.
Furthermore, these results support observations on follicle
FIG. 3. AUC of FSH (top panel), E2
(middle panel), and total follicle num-
ber (bottom panel) during two periods in
the control cycle and intervention cycle
in 23 regularly cycling women. Period 1
is defined as DayLH114 until DayLH119,
and period 2 from DayLH119 until
DayLH124. Boxes indicate 25th and 75th
percentiles, with the horizontal line
representing the median value. Whis-
kers span the range between the 5th
and 95th percentiles of the data. a, Sig-
nificantly different (P , 0.05) compar-
ing a similar period from the interven-
tion cycle vs. the control cycle. b,
Significantly different (P , 0.05) com-
paring a similar period from group B vs.
group A. c, P 5 0.07, comparing a sim-
ilar period in group B vs. group A.
FSH WINDOW AND FOLLICLE DEVELOPMENT 1297
 at Medical Library Erasmus MC on December 12, 2006 jcem.endojournals.orgDownloaded from 
development during and after the pill-free interval in oral
contraceptive pill users. During this period, FSH levels may
reach normal follicular phase concentrations, sufficient to
initiate follicle recruitment (4). Extension of the pill-free in-
terval may thus result in dominant follicle development de-
spite decreasing FSH concentrations due to reinitiation of pill
intake (40). In conclusion, elevation of FSH levels high above
the threshold level for a short period of time in the early
follicular phase does not increase the number of dominant
follicles. When a decrease in FSH is prevented in the late
follicular phase augmented sensitivity for FSH allows several
follicles to gain dominance. Follicle dominance may not be
dependent on FSH levels as rigidly as previously assumed.
These observations support the FSH window concept and
may exhibit clinical implications for ovulation induction
treatment and oral contraceptive use.
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